FI950910A0 - Fettsyraderivat - Google Patents

Fettsyraderivat

Info

Publication number
FI950910A0
FI950910A0 FI950910A FI950910A FI950910A0 FI 950910 A0 FI950910 A0 FI 950910A0 FI 950910 A FI950910 A FI 950910A FI 950910 A FI950910 A FI 950910A FI 950910 A0 FI950910 A0 FI 950910A0
Authority
FI
Finland
Prior art keywords
fatty acid
acid derivatives
derivatives
fatty
acid
Prior art date
Application number
FI950910A
Other languages
English (en)
Finnish (fi)
Other versions
FI950910A (sv
Inventor
David Frederick Horrobin
Philip Knowles
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of FI950910A0 publication Critical patent/FI950910A0/sv
Publication of FI950910A publication Critical patent/FI950910A/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10Salicylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/86Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/281-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI950910A 1994-03-01 1995-02-28 Fettsyraderivat FI950910A (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9403857A GB9403857D0 (en) 1994-03-01 1994-03-01 Fatty acid derivatives

Publications (2)

Publication Number Publication Date
FI950910A0 true FI950910A0 (sv) 1995-02-28
FI950910A FI950910A (sv) 1995-09-02

Family

ID=10751062

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950910A FI950910A (sv) 1994-03-01 1995-02-28 Fettsyraderivat

Country Status (12)

Country Link
US (1) US5603959A (sv)
EP (1) EP0675103A3 (sv)
JP (1) JPH07304688A (sv)
KR (1) KR950032062A (sv)
CN (1) CN1117484A (sv)
AU (1) AU703550B2 (sv)
CA (1) CA2143604A1 (sv)
FI (1) FI950910A (sv)
GB (1) GB9403857D0 (sv)
NO (1) NO950785L (sv)
NZ (1) NZ270589A (sv)
ZA (1) ZA951661B (sv)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40546E1 (en) * 1996-05-01 2008-10-21 Scarista, Ltd. 1,3-Propane diol esters and ethers and methods for their use in drug delivery
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
EP0823897B1 (en) * 1995-05-01 2004-07-28 Scarista Limited Nicotinic acid esters and pharmaceutical compositions containing them
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
CN1237162A (zh) * 1996-11-12 1999-12-01 美国家用产品公司 Cox-2的茚抑制剂
US5869524A (en) * 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
WO1998027972A2 (en) * 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
JP2002502881A (ja) * 1998-02-13 2002-01-29 ニュートラマックス ラボラトリーズ,インコーポレイテッド 結合組織を保護、治療、および修復するための薬剤および方法
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US6572871B1 (en) * 1999-01-06 2003-06-03 W. Edward Church Pain treatment method and apparatus using heating wrap and analgesic cream
US20040073258A1 (en) * 1999-01-06 2004-04-15 Church W. Edward Body tissue and skin treatment method using pulsing heating pad and topical cream
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
WO2001093680A1 (en) * 2000-06-02 2001-12-13 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
WO2002009725A1 (en) * 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
WO2002009691A1 (en) 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
US6838451B1 (en) 2000-08-02 2005-01-04 Pharmanutrients Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
US6927239B1 (en) * 2000-08-02 2005-08-09 Pharmanutrients Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
WO2002083151A2 (en) * 2000-12-14 2002-10-24 Tufts University Compositions and methods for treating an arthritic condition
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
JP3977162B2 (ja) * 2002-06-21 2007-09-19 株式会社バンダイナムコゲームス キャラクタ情報管理装置、プログラム及び情報記憶媒体
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス, インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
US20050154059A1 (en) * 2004-01-13 2005-07-14 Cook Mark E. Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
US20090155903A1 (en) * 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0516803A (pt) * 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
EP1983977A4 (en) * 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008103753A2 (en) * 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2008153722A1 (en) * 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
MX2011000273A (es) 2008-07-08 2011-05-23 Catabasis Pharmaceuticals Inc Salicilatos acetilados con acidos grasos y sus usos.
US9085527B2 (en) * 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
US20110229565A1 (en) * 2008-09-17 2011-09-22 Karp Jeffrey M Drug Delivery Composition Comprising a Self-Assembled Gelator
BRPI0919979A2 (pt) 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
ES2768091T3 (es) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
SG10201500431SA (en) 2009-09-01 2015-03-30 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
US20110064813A1 (en) * 2009-09-16 2011-03-17 Charles Vaughn Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
US8715699B2 (en) * 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
JP2013517322A (ja) * 2010-01-20 2013-05-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス サリチレート脂肪酸誘導体
KR20130026428A (ko) * 2010-03-04 2013-03-13 아마린 파마, 인크. 심혈관 질환을 치료 및/또는 예방하기 위한 조성물 및 방법
WO2011109681A1 (en) * 2010-03-05 2011-09-09 Catabasis Pharmaceuticals, Inc. Fatty acid cox inhibitor derivatives and their uses
PL2544536T3 (pl) * 2010-03-11 2019-05-31 Kempharm Inc Koniugaty kwasów tłuszczowych z kwetiapiną, sposób ich wytwarzania i stosowania
WO2011116312A1 (en) * 2010-03-19 2011-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
EP2593476A2 (en) * 2010-07-16 2013-05-22 Ablynx N.V. Modified single domain antigen binding molecules and uses thereof
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CN103384521A (zh) * 2010-12-21 2013-11-06 雀巢产品技术援助有限公司 用于预防和治疗骨关节炎的方法和组合物
US9730884B2 (en) * 2011-09-29 2017-08-15 Plx Opco Inc. pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
BR112014032905B1 (pt) 2012-06-29 2022-02-22 Amarin Pharmaceuticals Ireland Limited Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR102530119B1 (ko) 2013-12-24 2023-05-08 버지니아 커먼웰스 유니버시티 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US9603869B2 (en) 2015-05-22 2017-03-28 University Of South Florida Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
AU2016335846B2 (en) 2015-10-08 2019-04-04 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN115837006A (zh) 2016-05-06 2023-03-24 布里格姆及妇女医院股份有限公司 用于向软骨中受控递送被囊封的药剂的二元自组装凝胶
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
JP7211974B2 (ja) 2017-05-08 2023-01-24 アリヴィオ セラピューティクス, インコーポレイテッド 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019349563B2 (en) 2018-09-24 2023-06-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
JP2023518822A (ja) 2020-03-26 2023-05-08 ピーエルエックス オプコ インコーポレイテッド pH依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2755224A1 (de) * 1976-12-15 1978-07-13 Procter & Gamble Schmerzen und entzuendungen linderndes mittel zur oertlichen anwendung
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
JPS5815940A (ja) * 1981-07-23 1983-01-29 Eisai Co Ltd ポリプレニル系化合物およびその製造方法ならびにそれを含有する医薬
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS60142941A (ja) * 1983-12-28 1985-07-29 Ono Pharmaceut Co Ltd ケトン化合物
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
IT1217589B (it) * 1988-05-13 1990-03-30 Pulitzer Italiana Agente antiinfiammatorio per la terapia dell'ipertrofia prostatica,sua preparazione e relative composizioni farmaceutiche
EP0510080A4 (en) * 1989-12-26 1992-12-02 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof

Also Published As

Publication number Publication date
ZA951661B (en) 1995-12-08
EP0675103A2 (en) 1995-10-04
US5603959A (en) 1997-02-18
KR950032062A (ko) 1995-12-20
CA2143604A1 (en) 1995-09-02
AU1348095A (en) 1995-09-07
AU703550B2 (en) 1999-03-25
GB9403857D0 (en) 1994-04-20
JPH07304688A (ja) 1995-11-21
FI950910A (sv) 1995-09-02
NO950785D0 (no) 1995-02-28
NZ270589A (en) 1997-06-24
NO950785L (no) 1995-09-04
EP0675103A3 (en) 1997-03-26
CN1117484A (zh) 1996-02-28

Similar Documents

Publication Publication Date Title
NO950785D0 (no) Fettsyrederivater
BR9510256A (pt) Derivados de ácido 3-aril-tetrônico
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
DE69703385D1 (de) Alkoxyessigsäure-derivate
NO990821D0 (no) Arylsulfonylamino-hydroksaminsyre-derivater
ATE248812T1 (de) Arylsulfonylhydroxamsäurederivate
DK1003720T3 (da) Aryloxyarylsulfonylaminohydroxamsyrederivater
NO952854D0 (no) 1-arylpyrimidin-derivater
DE59508427D1 (de) 3-aryl-4-hydroxy-delta 3 -dihydrothiophenon-derivate
DE69429927D1 (de) Fettsäure-abgabesystem
HUP0000937A3 (en) New fatty acid derivatives
ZA963103B (en) Fatty acid derivatives
DE69606053D1 (de) Modifizierte fluorsulfonsäure
DE69430587D1 (de) Pyrimidin-acyclonukleosid-derivate
BR9509793A (pt) Derivados de tiofeneno
DK0718275T3 (da) Kvaternære triethanolaminfedtsyreestere
EE9600011A (et) Uudsed dialkoksü-püridinüül-bensimidasooli derivaadid
ATE230734T1 (de) 3-alkoxyisoxazol-4-yl-substituierte 2- aminocarbonsäurederivate
DE69527786D1 (de) Diaminomethyliden-derivate
NO965233D0 (no) Deacetoksytaksol-derivat
DE59402621D1 (de) Fluor-trifluormethylbenzoesäure-Derivate
DE59509209D1 (de) Diphenyloxazolin-derivate
NO970144D0 (no) Trifluormetylkinolinkarboksylsyre-derivat
EE04061B1 (et) Metüleenbisfosfoonhappe derivaadid
NO964914D0 (no) Naftokinonderivater